Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy have?
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy has 130 citations in the OpenAlex counts ScholarIQ stores.
When was Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy published?
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy has 2021 year in the ScholarIQ index.
What is the open-access status of Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy?
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy has bronze oa status in the ScholarIQ index.
What is the DOI of Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy?
The DOI for Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy is on the source record.
What is the PMID of Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy?
The PMID for Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy is on the source record.
What is the OpenAlex record for Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy?
The OpenAlex for Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy is on the source record.